Local Anesthetics: Pharmacology and Clinical Considerations

Core Review

Mechanism of Action: Sodium Channel Blockade

Local anesthetics reversibly block voltage-gated sodium (Na+) channels in the nerve cell membrane, preventing the influx of Na+ ions required for depolarization. By inhibiting depolarization, they prevent the propagation of action potentials along the nerve fiber. Pain sensation is blocked first (small, unmyelinated C fibers and thinly myelinated Aδ fibers), followed by temperature, touch, and pressure sensation. Motor fibers (large, myelinated Aα fibers) are blocked last.

Key pharmacological principle — state-dependent block: Local anesthetics preferentially bind to Na+ channels in the OPEN or INACTIVATED state. This means they are more effective on nerves that are actively firing — a concept called "use-dependent" or "frequency-dependent" block. Clinically, this explains why an already painful (actively firing) nerve may be more susceptible to blockade.

Differential blockade: Smaller nerve fibers are blocked more readily than larger fibers. Myelinated fibers are blocked more readily than unmyelinated fibers (because LAs only need to block at nodes of Ranvier). However, because C fibers (pain) are unmyelinated but very small, they are blocked first. The typical order of blockade: pain → temperature → touch → pressure → motor. Recovery occurs in reverse order.

Chemical Structure and Classification

All local anesthetics share a common structure: Lipophilic (aromatic) group — Intermediate chain (ester or amide linkage) — Hydrophilic (amino) group

The nature of the intermediate linkage defines the two major classes:

Amide Local Anesthetics

The intermediate chain contains an AMIDE (-NHCO-) linkage. Amides are metabolized primarily in the LIVER (hepatic microsomal enzymes, CYP450 system).

Amides in current dental use:

• Lidocaine (Xylocaine): The "gold standard" and most widely used dental LA. Rapid onset, moderate duration (pulpal ~60 min, soft tissue ~3-5 hours with epinephrine). pKa = 7.7-7.9. Lipid solubility = 2.9. Protein binding = 64%.
• Mepivacaine (Carbocaine, Polocaine): Available with vasoconstrictor AND as a plain (3%) solution. Slightly shorter duration. Least vasodilating amide — the 3% plain solution can provide adequate pulpal anesthesia for short procedures (~20-30 min pulpal) without a vasoconstrictor. pKa = 7.6. Protein binding = 77%.
• Prilocaine (Citanest): Similar potency and onset to lidocaine. Metabolized to ortho-toluidine, which can cause methemoglobinemia at high doses. pKa = 7.9. Protein binding = 55%. Often used when epinephrine is relatively contraindicated.
• Bupivacaine (Marcaine): Long-acting LA. High lipid solubility (28), high protein binding (95%), slow onset (pKa = 8.1). Pulpal anesthesia duration: ~90-120+ minutes with epinephrine. Soft tissue anesthesia may last 6-12 hours. Cardiotoxic — more likely to cause severe cardiac arrhythmias with accidental intravascular injection. Binds avidly to cardiac Na+ channels and dissociates very slowly.
• Articaine (Septocaine): Unique — contains a thiophene ring (instead of a benzene ring) and an additional ester side chain. Articaine is classified as an amide but undergoes partial hydrolysis by plasma esterases in addition to hepatic metabolism. pKa = 7.8. High lipid solubility. Excellent bone penetration (controversial but clinically observed). The only amide with a shorter half-life (~30 min) due to dual metabolism. Contains a sulfite preservative in the vasoconstrictor-containing formulation — important for patients with sulfite sensitivity/allergy.

Ester Local Anesthetics

The intermediate chain contains an ESTER (-COO-) linkage. Esters are metabolized primarily in the PLASMA by pseudocholinesterase (plasma cholinesterase, butyrylcholinesterase). Their plasma half-life is very short (seconds to minutes).

Esters in current dental use:

• Procaine (Novocaine): Historically the first injectable LA. Short duration, high allergenicity. Rarely used today for injection. Occasionally used as an intramuscular antibiotic diluent.
• Benzocaine: Topical LA (NOT for injection). Low systemic toxicity because it is poorly absorbed. Used in topical gels, sprays, and lozenges. May cause methemoglobinemia, particularly with excessive topical application (benzocaine spray has been restricted by FDA for this reason).
• Tetracaine (Pontocaine): Potent, long-acting ester. Used topically and (less commonly) for spinal anesthesia.

Allergy and cross-reactivity:

• TRUE allergy to amide LAs is extremely rare (<1% of reported "allergic" reactions)
• Ester LAs are more commonly allergenic (the metabolite para-aminobenzoic acid [PABA] is the allergenic determinant)
• Cross-reactivity: amide-allergic patients are NOT allergic to esters (and vice versa), because the allergenic determinants differ. Esters → PABA; amides → no PABA.
• Most "allergic" reactions to LA in a dental setting are actually: (a) psychogenic (vasovagal syncope), (b) toxic (inadvertent intravascular injection), or (c) a reaction to the vasoconstrictor (epinephrine-induced tachycardia/palpitations) or preservative (sulfites in articaine/epinephrine formulations; methylparaben — now removed from most dental cartridges)

Key Pharmacological Properties

pKa and Onset of Action

pKa: The pH at which 50% of the LA molecules are in the uncharged (free base, lipid-soluble) form and 50% are in the charged (ionized, water-soluble) form. This is the single most important determinant of ONSET.

• Uncharged (free base) form: Lipid-soluble — CAN cross the nerve membrane to reach the Na+ channel binding site
• Charged (ionized) form: Water-soluble — CANNOT cross the nerve membrane; but once inside the cell, the charged form binds to the Na+ channel

At physiological pH (7.4), an LA with a LOWER pKa will have a GREATER proportion in the uncharged form → faster onset. An LA with a HIGHER pKa will have a smaller proportion in the uncharged form → slower onset.

Clinical implication — infection and acidosis: In inflamed/infected tissue, the pH is LOWER (acidic, often pH 5-6). At a lower pH, a smaller proportion of LA is in the uncharged (lipid-soluble) form → POORER penetration → REDUCED efficacy. This is the mechanism by which infection (or tissue acidosis) reduces LA effectiveness — NOT that bacteria "destroy" the LA, but that the acidic environment shifts the equilibrium toward the charged form. This is why attempting to anesthetize an acutely infected area is often unsuccessful.

Lipid Solubility and Potency

Higher lipid solubility → greater penetration through the nerve membrane → greater POTENCY. Bupivacaine (lipid solubility ~28) is more potent than lidocaine (~2.9), which is more potent than procaine (~1).

Protein Binding and Duration of Action

Higher protein binding → LA binds more tightly to the Na+ channel protein → dissociates more slowly → LONGER DURATION. Bupivacaine (95% protein-bound) has the longest duration of dental LAs. Lidocaine (64%) has moderate duration. Prilocaine (55%) and articaine have shorter durations.

This is why high protein binding also means greater cardiotoxicity risk: Bupivacaine binds tightly to cardiac Na+ channels and dissociates slowly — if accidentally injected intravascularly, bupivacaine can cause severe, difficult-to-treat cardiac arrhythmias.

Vasoconstrictors in Local Anesthetic Solutions

Vasoconstrictors are added to LA solutions for three purposes:

1. Decrease systemic absorption of the LA → reduce the peak blood level → reduce systemic toxicity
2. Prolong the duration of anesthesia by keeping the LA at the injection site longer
3. Provide hemostasis at the surgical site

Epinephrine (adrenaline) is the most common vasoconstrictor in dental cartridges. Common dilutions: 1:50,000, 1:80,000, 1:100,000, 1:200,000.

Concentrations (mg/mL):

• 1:1,000 = 1 mg/mL
• 1:50,000 = 0.02 mg/mL
• 1:80,000 = 0.0125 mg/mL
• 1:100,000 = 0.01 mg/mL
• 1:200,000 = 0.005 mg/mL

Other vasoconstrictors:

• Levonordefrin (Neo-Cobefrin): Synthetic sympathomimetic. Used at 1:20,000. Less potent than epinephrine.

Epinephrine — clinical safety considerations: Epinephrine is an endogenous catecholamine that the body produces and metabolizes efficiently. In healthy patients, the small doses in dental cartridges are well-tolerated. The primary clinical concern is in patients with significant cardiovascular disease.

According to current American Heart Association (AHA) and American Dental Association (ADA) guidance:

• In patients with stable cardiovascular disease (stable angina, remote MI [>6 months], controlled hypertension, controlled heart failure), the use of epinephrine-containing LA is generally considered acceptable with appropriate aspiration and limitation of the total epinephrine dose
• For patients with UNSTABLE cardiovascular disease (unstable angina, recent MI, severe/uncontrolled hypertension, uncontrolled arrhythmias, decompensated heart failure), elective dental treatment should be deferred pending medical optimization
• The decision to use or limit epinephrine should be individualized based on the patient's current cardiovascular status

Sulfite preservatives: Sodium metabisulfite (or potassium metabisulfite) is added to epinephrine-containing LA cartridges as an antioxidant (prevents epinephrine oxidation). Patients with sulfite sensitivity/allergy (most commonly severe asthmatics) should receive epinephrine-free LA or an LA with levonordefrin (which also may contain sulfites in some formulations — check product labeling). True sulfite allergy is relatively rare.

Local Anesthetic Systemic Toxicity (LAST)

Systemic toxicity occurs when plasma LA concentration exceeds the threshold for adverse effects, most commonly from accidental INTRAVASCULAR INJECTION or, less commonly, from administration of an excessive total dose.

The progression of LAST signs and symptoms (in order of increasing plasma concentration):

1. CNS excitation (early): Circumoral paresthesia/numbness (tingling around the mouth, tongue), metallic taste, lightheadedness, tinnitus, visual disturbances, slurred speech, muscle twitching, shivering
2. CNS depression (later, with higher concentrations): Drowsiness, disorientation, loss of consciousness, respiratory depression
3. CNS excitation — seizures: Tonic-clonic seizures
4. Cardiovascular depression: Hypotension, bradycardia, cardiac arrhythmias, cardiovascular collapse

Why does CNS excitation precede depression? LAs initially block inhibitory GABA-ergic neurons in the CNS (removing inhibition → excitation), then at higher concentrations block excitatory pathways (→ depression).

Bupivacaine cardiotoxicity: Bupivacaine is more cardiotoxic than lidocaine because it binds more tightly to cardiac Na+ channels and dissociates very slowly ("fast-in, slow-out" kinetics). This makes bupivacaine-induced cardiac arrhythmias difficult to treat. Bupivacaine is therefore used cautiously in dental settings and avoided for regional blocks where large volumes are used.

Methemoglobinemia: Prilocaine is metabolized to ortho-toluidine, which oxidizes hemoglobin iron from Fe2+ (ferrous) to Fe3+ (ferric), forming methemoglobin, which cannot carry oxygen. Benzocaine (topical ester) can also cause methemoglobinemia. Clinical signs: cyanosis with normal PaO2, chocolate-brown blood. Treatment: methylene blue (1-2 mg/kg IV).

Factors Affecting LA Efficacy

• Anatomical barriers: Dense cortical bone (mandibular posterior), accessory innervation (mylohyoid nerve, cervical plexus)
• Tissue pH: Low pH (infection, inflammation) → ionized LA → reduced membrane penetration → reduced efficacy
• Vascularity: Highly vascular areas absorb LA faster → shorter duration
• Injection technique: Accurate needle placement at the target nerve
• Anatomic variation: Bifid inferior alveolar nerve, bifid mandibular canal, presence/absence of MSA nerve

Comparative Summary: Common Dental Local Anesthetics

NOTE: Specific maximum recommended doses (MRDs) in mg/kg and mg per absolute patient are deliberately omitted. Consult current product labeling (FDA-approved package inserts).

Clinical Application

Selection of the appropriate LA for a given procedure involves consideration of: (1) required duration of pulpal and soft tissue anesthesia, (2) patient's medical history and medications, (3) need for hemostasis, (4) allergy history (amide vs. ester), and (5) the planned procedure. The most common cause of LAST is accidental intravascular injection — meticulous aspiration technique is the single most important preventive measure. For procedures of long duration, bupivacaine provides extended anesthesia, but the clinician must counsel patients about prolonged soft tissue anesthesia (risk of self-inflicted trauma to lips and tongue, especially in children).

Common Traps

• Confusing amide and ester metabolism: amides = hepatic; esters = plasma
• Thinking a patient allergic to an ester LA is allergic to amides — they are NOT cross-reactive
• Confusing which property determines onset (pKa) vs. potency (lipid solubility) vs. duration (protein binding)
• Forgetting that infection reduces efficacy NOT by bacterial destruction but by low pH favoring the charged (non-penetrating) form
• Thinking bupivacaine is preferred for routine, short procedures because it "lasts longer" — the prolonged soft tissue anesthesia is often a DISADVANTAGE